Valeo Pharma Inc. (TSE:VPH – Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 120873 shares trading hands. The stock had previously closed at C$0.07.
Valeo Pharma Stock Down 7.7 %
The business’s fifty day moving average is C$0.09 and its 200 day moving average is C$0.12. The stock has a market cap of C$5.92 million, a PE ratio of -0.18 and a beta of 2.39.
Valeo Pharma (TSE:VPH – Get Free Report) last released its quarterly earnings data on Thursday, June 13th. The company reported C($0.08) earnings per share for the quarter, missing the consensus estimate of C($0.05) by C($0.03). The company had revenue of C$14.13 million during the quarter, compared to analysts’ expectations of C$15.50 million.
About Valeo Pharma
Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.
Featured Stories
- Five stocks we like better than Valeo Pharma
- Investing in Construction Stocks
- Emerging Markets: What They Are and Why They Matter
- Industrial Products Stocks Investing
- Recession or Not, These 3 Stocks Are Winners
- Business Services Stocks Investing
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Valeo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.